• ABBV

AbbVie raises profit forecast as CEO cites business "momentum"

AbbVie raises its income forecast and dividend after strong Q3 results, highlighting growth from Skyrizi amid declining Humira sales.

• ABBV

AbbVie raises 2024 profit forecast on strong sales of key drugs Skyrizi, Rinvoq

• ABBV

AbbVie earnings beat by $0.08, revenue topped estimates

AbbVie reported Q3 EPS of $3.00, exceeding estimates; revenue was $14.46B. It projects FY 2024 EPS of $10.90-$10.94 and remains financially healthy.

• 1YMZ24
• ABBV
• AMD
• CAT
• CL
• DJI
• ESZ24
• GOOG
• IXIC
• LCO
• LLY
• NQZ24
• US500

Alphabet and AMD report, more earnings and GDP ahead - what's moving markets

US stock futures rise ahead of corporate earnings and economic data, with Alphabet's solid results contrasting AMD's disappointing forecast. Oil prices also gain as US inventories drop unexpectedly.

• ABBV

AbbVie cuts 2024 profit forecast citing R&D expenses

AbbVie revised its 2024 profit forecast down due to $82 million in expenses, projecting adjusted profit per share between $10.67 and $10.87, below analyst expectations.

• ABBV

AbbVie's Parkinson's disease drug meets main goal in late-stage trial

AbbVie's tavapadon shows significant improvement in early Parkinson's disease patients in a late-stage trial, demonstrating potential as a new once-daily treatment.